Reneo Pharma Ltd
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| An Open Label, Long Term Safety Study of REN001 in Primary Mitochondrial Myopathy Patients (Stride Ahead) (NCT05267574) | Reneo Pharma Ltd | 2022-02-01 |
| An Efficacy and Safety Study of 24 Week Treatment With Mavodelpar (REN001) in Primary Mitochondrial Myopathy Patients (NCT04535609) | Reneo Pharma Ltd | 2021-05-21 |
| A Prospective Study of the Disease Characteristics of Adult Patients With Long Chain Fatty Acid Oxidation Disorders (NCT04482049) | Reneo Pharma Ltd | 2021-01-15 |
| A Study of the Safety of REN001 in Patients With McArdle Disease (NCT04226274) | Reneo Pharma Ltd | 2019-12-10 |
| A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy (NCT03862846) | Reneo Pharma Ltd | 2019-05-10 |
| A Phase 1b Study of the Safety of REN001 in Patients With Fatty Acid Oxidation Disorders (NCT03833128) | Reneo Pharma Ltd | 2019-04-04 |
Track Reneo Pharma Ltd automatically
Every clearance here is in the API, with alerts when new ones post.